(3,5-difluorophenyl)tributyltin | 231291-15-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3,5-difluorophenyl)tributyltin
• 英文别名: 1,3-difluoro-4-(tributyltin)benzene
• CAS: 231291-15-9
• 化学式: C₁₈H₃₀F₂Sn
• 分子量: 403.143
• InChiKey: RXSZGRQTMPRFHC-UHFFFAOYSA-N

物化性质

• 沸点：
  369.2±52.0 °C(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.02
• 重原子数：
  21
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (3,5-difluorophenyl)tributyltin 在 盐酸 、 四(三苯基膦)钯 、 一水合肼 、 sodium nitrite 作用下， 以 甲醇 、 xylene 为溶剂， 反应 24.5h， 生成 5-(3,5-Difluoro-phenyl)-nicotinoyl azide
  参考文献：
  名称：

  Biarylcarbamoylindolines Are Novel and Selective 5-HT_2C Receptor Inverse Agonists:  Identification of 5-Methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a Potential Antidepressant/Anxiolytic Agent

  摘要：

  The evolution, synthesis, and biological activity of a novel series of 5-HT2C receptor inverse agonists are reported. Biarylcarbamoylindolines have been identified with excellent 5-HT2C affinity and selectivity over 5-HT2A receptors. In addition, (pyridyloxypyridyl)carbamoylindolines have been discovered with additional selectivity over the closely related 5-HT2B receptor. Compounds from this series are inverse agonists at the human cloned 5-HT2C receptor, completely abolishing basal activity in a functional assay. The new series have reduced P450 inhibitory liability compared to a previously described series of 1-(3-pyridylcarbamoyl)indolines (Bromidge et al. J. Med. Chem. 1998, 41, 1598) from which they evolved. Compounds from this series showed excellent oral activity in a rat mCPP hypolocomotion model and in animal models of anxiety. On the basis of their favorable biological profile, 32 (SB-228357) and 40 (SB-243213) have been selected for further evaluation to determine their therapeutic potential for the treatment of CNS disorders such as depression and anxiety.

  DOI：

  10.1021/jm990388c
• 作为产物：
  描述：

  1-溴-3,5-二氟苯 、 三丁基氯化锡 在 CH₃CH₂CH₂CH₂Li 作用下， 以 乙醚 、 正己烷 为溶剂， 以65%的产率得到(3,5-difluorophenyl)tributyltin
  参考文献：
  名称：

  Highly Fluorinated Dithieno[3,2-b:2′,3′-d]phospholes with Stabilized LUMO Levels

  摘要：

  DOI：

  10.1021/om800874d

文献信息

• Palladium(II)-mediated 11C-carbonylative coupling of diaryliodonium salts with organostannanes—a new, mild and rapid synthesis of aryl [11C]ketones
  作者：Mohammed H. Al-Qahtani、Victor W. Pike

  DOI：10.1039/a907803g

  日期：——

  [11C]carbonylative coupling of diaryliodonium salts with aryltributylstannanes for 1 min in DME–water (4∶1 v/v) at RT gives a new mild and rapid route to aryl [11C]ketones. Substituted aryltributylstannanes couple with diphenyliodonium bromide to give substituted [11C]benzophenones in generally very high radiochemical yield (>98%, decay-corrected), while diphenyliodonium tosylates, bearing one or two

  钯（II）介导二芳碘鎓盐与芳基三丁基锡烷的[ 11 C]羰基偶联1分钟。二甲醚–水 （41：1 v / v）在RT处提供了一条新的温和而快速的路线 芳基[ 11 C]酮。取代的芳基三丁基锡烷与溴化二苯碘鎓通常以非常高的放射化学收率（> 98％，经衰变校正）得到取代的[ 11 C]二苯甲酮，而二苯碘phenyl甲苯磺酸盐（在一个环上带有一个或两个取代基）与苯基三丁基锡烷得到取代的（30–43％）和未取代的[ 11 C]二苯甲酮（47–66％）的混合物。这些反应对于将回旋加速器产生的碳11（t 1/2  = 20.4分钟）引入到预期的放射性示踪剂中以在医学成像中的应用具有很高的吸引力。正电子 发射断层扫描。
• Chemical compounds
  申请人：Brown Lee Matthew

  公开号：US20050288515A1

  公开（公告）日：2005-12-29

  Oxazole derivatives, which are useful as VEGFR2, CDK2, and CDK4 inhibitors are described herein. The described invention also includes methods of making such oxazole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

  本文介绍了一种作为VEGFR2、CDK2和CDK4抑制剂有用的噁唑衍生物。所述发明还包括制备此类噁唑衍生物的方法以及在治疗增生性疾病中使用它们的方法。
• CHEMICAL COMPOUNDS
  申请人：Brown Lee Matthew

  公开号：US20070142437A1

  公开（公告）日：2007-06-21

  Oxazole derivatives, which are useful as VEGFR2, CDK2, and CDK4 inhibitors are described herein. The described invention also includes methods of making such oxazole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

  本文描述了一种有用的噁唑衍生物，可作为VEGFR2、CDK2和CDK4抑制剂。所述发明还包括制备这种噁唑衍生物的方法，以及在治疗高增殖性疾病方面使用它们的方法。
• 1,3-Oxazole compounds for the treatment of cancer
  申请人：SmithKline Beecham Corporation

  公开号：US07189712B2

  公开（公告）日：2007-03-13

  Oxazole derivatives, which are useful as VEGFR2, CDK2, and CDK4 inhibitors are described herein. The described invention also includes methods of making such oxazole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

  本文描述了一种作为VEGFR2、CDK2和CDK4抑制剂有用的噁唑衍生物。所述发明还包括制备这种噁唑衍生物的方法，以及在治疗过度增生性疾病中使用它们的方法。
• Al-Qahtani; Pike, Journal of labelled compounds and radiopharmaceuticals, 1999, vol. 42, # SUPPL. 1, p. S75-S77
  作者：Al-Qahtani、Pike

  DOI：——

  日期：——